Gill A. Webster, PhD


New Zealand

Gill A. Webster, PhD, is chief scientific officer at Virionyx Corporation Ltd.


The Therapeutic Vaccine Potential of MIS416 Adjuvant

This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.